Please login to the form below
Vertex Pharma
This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.
Vertex to lead development of CRISPR Therapeutics-partnered gene therapy
as we bring forward our broad gene and cell-based therapeutics portfolio,” said Jeffrey Leiden, executive chairman of Vertex. ... Along with Vertex/CRISPR Therapeutics, bluebird bio is also seeking to bring its gene therapy LentiGlobin for SCD (bb1111)
Latest news
-
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex gained VX-880 from its previous acquisition of Semma Therapeutics for $950m in September 2019. ... This will help to protect the islet cells from immune rejection, Vertex said in a statement.
-
Vertex’s triple combination CF therapy to become available on the NHS
NHS England has reached an agreement with Vertex for immediate access to the pharma company’s transformative triple combination therapy for cystic fibrosis (CF). ... eligible will be able to benefit from access to Vertex’s other CF drugs.
-
Vertex continues upward trajectory with French Orkambi deal
The American pharma giant reached an agreement with the English regulatory bodies in October, for access to Orkambi and Vertex’s other CF treatments Symkevi (tezacaftor-ivacaftor) and Kalydeco (ivacaftor). ... Vertex has also submitted the triple
-
Vertex reveals promising data from first CRISPR-treated patients
beta thalassemia,” said Jeffrey Leiden (pictured left), president and chief executive officer of Vertex. ... Vertex paid CRISPR Therapeutics $105m upfront in 2015, with up to $420m in milestone payments, to tap into its gene-editing expertise.
-
Vertex, NHS England and NICE finally reach agreement for Orkambi
to treat the underlying cause of their disease,” said Ludovic Fenaux (pictured right), senior vice president, Vertex International. ... We are pleased an agreement has been reached between NHS England and Vertex that brings these medicines to patients.
Vertex gains FDA fast track designation for diabetes stem cell therapy
Vertex’s triple combination CF therapy to become available on the NHS
Vertex continues upward trajectory with French Orkambi deal
Vertex, NHS England and NICE finally reach agreement for Orkambi
More from news
Approximately 6 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Health trust in a COVID-19 world – a unique opportunity for pharma
There were also some high-profile reimbursement stand-offs between pharma and the NHS (eg, Vertex/Orkambi). ... to the pharma industry, which is seen as being responsible for the high price of medicines).
-
The Cystic Fibrosis Buyers’ Club
This includes overriding pharma patents – something the group is advocating in relation to three drugs – Vertex’s cystic fibrosis treatment Orkambi, Pfizer’s breast cancer treatment Ibrance and Roche’s breast ... Meticulous preparations. The
-
Vertex: a vision of treating all CF patients worldwide draws closer
Its high prices are controversial, but Vertex also embodies the best of biopharma drug development. ... The failure of Proteostasis has led analysts to upgrade forecasts for Vertex’s own franchise.
-
The Orkambi blame game
The deadlock between pharma company Vertex and NHS England over cystic fibrosis drug Orkambi was played out in a parliamentary hearing in London on 7 March, when the company’s CEO ... NHS England accusing Vertex of being an“extreme outlier” and
-
2019: CRISPR and therapeutic gene editing comes of age
The green light came after a delay of around a year caused by manufacturing issues, which allowed another candidate from CRISPR Therapeutics and Vertex Pharma - CTX001 for the rare blood disease
Health trust in a COVID-19 world – a unique opportunity for pharma
The Cystic Fibrosis Buyers’ Club
Vertex: a vision of treating all CF patients worldwide draws closer
The Orkambi blame game
2019: CRISPR and therapeutic gene editing comes of age
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Vertex poaches new finance chief from Ironwood Pharmaceuticals
Boston-based biotech company appoints Tom Graney. Vertex lured Tom Graney away from Ironwood Pharmaceuticals, appointing him as its new senior vice president and chief financial officer. ... Tom has the ideal blend of financial acumen, leadership skills,
-
BMS appoints three independent directors
Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief
Vertex poaches new finance chief from Ironwood Pharmaceuticals
BMS appoints three independent directors
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Will most electronic consumer goods turn into medical devices after the MDR?
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Biogen’s Vumerity recommended by CHMP in MS
- All change – how untangling human behaviour can encourage better health
- Solving healthcare problems
- New data from Moderna supports COVID boosters
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- New data advances AstraZeneca’s “revolution in oncology”
- EU identifies first five ‘promising’ COVID-19 drugs as part of therapeutics strategy
- Future of MHRA uncertain amid Brexit-fuelled shake up
- All change – how untangling human behaviour can encourage better health
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
